Talk:Undifferentiated pleomorphic sarcoma

Medicine: Dermatology / Pathology Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by the Dermatology task force.
	This article is supported by the Pathology task force (assessed as Mid-importance).

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Undifferentiated pleomorphic sarcoma.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Tip: Anchors are case-sensitive in most browsers.

This article links to one or more target anchors that no longer exist.

[[Rhabdomyosarcoma#Rhabdomyosarcoma|Pleomorphic rhabdomyosarcoma]]

Please help fix the broken anchors. You can remove this template after fixing the problems. | Reporting errors

note

The histopathologic diagnosis of malignant fibrous histiocytoma is controversial, as there is no cell called the "fibrous histocyte". Probably a more accurate morphologic diagnosis is anaplastic soft tissue sarcoma with multinucleated cells.

The entity malignant fibrous histiocytoma in rodent toxicology is entirely different from the human tumour described here, it occurs predominantly at the site of repeated subcutaneous injections. Rodents have been shown to develop MFH at the sites of implantation of inert foreign materials and the sites of injection of a number of otherwise innocuous chemicals (e.g., glucose, fructose). (1) Haseman, J., J. Bourbina, and S. Eustis. 1994. Effect of individual housing and other experimental design factors on tumour incidence in B6C3F1 mice. Fundam. Appl. Toxicol. 23:44–52. (2) Berenblum, I. 1974. Carcinogenesis as a biological problem. Amsterdam: North Holland Publishing. (3) Grasso, P., and L. Golberg. 1967. Subcutaneous sarcoma as an index of carcinogenic potency. Food Cosmet. Toxicol. 4:297–320. Farmacol (talk) 13:35, 13 February 2008 (UTC)[reply]

malignant fibrous histiocytoma

the case is reviewed at the request of tumer board for assesment of grade the proposed grading is according to the amount ofmyxoid stroma the current tumer demonstrates less then 50% of myxoid stroma with spindle cells displaying mild to moderate atypia  —Preceding unsigned comment added by 76.11.37.27 (talk) 19:05, 16 January 2009 (UTC)[reply]